This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
by Zacks Equity Research
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
ALKSPositive Net Change LQDAPositive Net Change KNSAPositive Net Change IMCRPositive Net Change
biotechs
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
by Zacks Equity Research
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change NMRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
by Zacks Equity Research
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
BEAMPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYPositive Net Change LQDAPositive Net Change MIRMPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
by Zacks Equity Research
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
RHHBYPositive Net Change JAZZPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs medical pharmaceuticals
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
by Zacks Equity Research
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
SNYNegative Net Change MGNXPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs medical
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYPositive Net Change LQDAPositive Net Change MIRMPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
by Zacks Equity Research
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
NVSPositive Net Change BAYRYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
by Zacks Equity Research
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
AZNPositive Net Change JNJNegative Net Change LQDAPositive Net Change INDVPositive Net Change
biotechs